Cyclic AMP raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
The Allan Hills meteorite, the first to be identified on Earth as having come from the Moon, was discovered in the Transantarctic Mountains in Antarctica by John Schutt and Ian Whillans during the international ANSMET (Antarctic Search for Meteorites) expedition. The meteorite's mass was 31.4 grams (1.11 oz), slightly more than one ounce. Although the lunar meteorite Yamato 791197 had been found on November 20, 1979, it would not be identified as such until 1984. In 1996, examination of the The collapse of a swinging bridge over the Guaíra Falls waterfall killed 32 tourists in Brazil, on the border of Brazil and Paraguay near Guaira, while they were seeking a close view of the waterfall. Those killed fell from a height of 120 feet (37 m) and drowned in the Paraná River. Survivors said that some people on the bridge had been swinging it when the supportive cables snapped.
"Magic" is a 1974 song by Scottish pop rock band Pilot and was the first hit single for the group. It was written by band members David Paton and Billy Lyall for their debut album From the Album of the Same Name.
The King's College Criteria or the King's College Hospital criteria were devised in 1989 to determine if there were any early indices of poor prognosis in patients with acute liver failure. Acute liver failure is defined as the onset of encephalopathy (altered mental status) or coagulopathy (altered bleeding tendencies) within 26 weeks of a patient diagnosed with liver disease. Patients with hepatitis B acquired at birth, Wilson's disease and autoimmune hepatitis are included if their disease was identified within the past 26 weeks. These patients are very ill, and have a very high risk of dying of their illness without adequate treatment which may include liver transplantation. It is important that physicians find ways of identifying patients with acute liver failure early in their course who will do poorly, and may require liver transplantation. The King's College Criteria have consistently shown excellent operating characteristics for determining prognosis in these patients. As liver transplantation becomes a more accessible option for patients with acute liver failure, the King's College Criteria serve a role in determining which patients may require transplantation.
==== Context ==== The announcement of the new cabinet is an attempt to resolve a political crisis between Pedro Castillo and the Congress of the Republic. On 24 November 2022, President Castillo delivered a speech to the nation in which he announced that he accepted the resignation of Aníbal Torres and also the appointment of a new cabinet. The resigning Prime Minister wanted to provoke a vote of confidence in Congress so that it would analyze a constitutional reform project to annul Congress in order to trigger referendums, particularly on the Constituent Assembly, a historic project of Castillo's, but the vote of confidence was denied by the presidency of Congress, dominated by the centre-right and the right. In that same speech, Pedro Castillo evokes the interpretation of Congress's decision not to allow the vote of confidence desired by the President of the council as an "express refusal of confidence" and considers this cabinet change legitimate.
Sources: en.wikipedia.org
Spasms occur when the part of the brain that controls movement malfunctions, causing involuntary muscle activity. A spasm may be a muscle contraction caused by abnormal nerve stimulation or by abnormal activity of the muscle itself.
=== Anraj Chabra === Anraj Chabra (Irfan Shamji) is a mild-mannered junior trader at Pierpoint working under Rishi, who frequently takes his anger out on him. Rishi uses Anraj's account to run a £300 million long on pound sterling against the US dollar, raising major flags at Pierpoint's risk management division (and jeopardizing Anraj's job and FCA license) until Rishi miraculously nets £18 million from the investment due to a last-minute tax cut by the UK government. Rishi also steals some of Anraj's money (claiming he is using it to bet on horse races) to gamble away at a casino. Anraj later admits that he is afraid to come to work because of Rishi's volatile behavior. Anraj and Sweetpea become friends over the course of their time at Pierpoint, in part due to their mutual frustration with Rishi. Anraj is briefly seen in series 4 attending the ALPHA conference, where Harper publicizes her findings on the fraudulent profits of fintech company Tender; he and Eric exchange a friendly glance.
== Conferences == In May 2010, the Foundation sponsored a conference on "Creatine in Health, Medicine and Sport", held at Downing College, Cambridge. This was followed by the first Macular Carotenoids Conference also held at Downing College in July 2011 which led to a book, Carotenoids and Retinal Disease. Further conferences on Macular Carotenoids at Downing College were held in 2013 and 2015. The BON (Brain and Ocular Nutrition) Conference is to be held 11–13 July 2018 again at Downing College, Cambridge.
Sources: en.wikipedia.org
=== Alkali disease === However, the incorporation of selenomethionine into tissue proteins and keratin in cattle, birds, and fish causes alkali disease. Alkali disease is characterized by emaciation, loss of hair, deformation and shedding of hooves, loss of vitality, and erosion of the joints of long bones.
== Other rhEGFs == Several other products containing recombinant human EGF have been marketed. The potencies of these products can differ by the expression system used, despite all intending to match the structure of human EGF. Instead of measuring by mass, the international unit system from the World Health Organization provides a way to describe the potency-adjusted amount of rhEGF. However, the WHO does not prescribe a specific way of measuring the potency. rhEGF bioassay remains a field in active development.
=== Kidnapping Act === The terms of the Kidnapping Act designate abduction, wrongful restraint or wrongful confinement for ransom as capital offences. The punishment in this case is death by hanging or imprisonment for life and, if the offender is not sentenced to death, he is also liable to caning.
It includes an intro song titled "Persona" rapped by group leader RM, who asks, "who am I?", and is confronted with various versions of himself with the words "persona", "shadow", and "ego", referring to Jung's theories. On 21 February 2020, the band released Map of the Soul: 7, which specifically focuses on Jung's "shadow" and "ego" theories. As part of the first phase of the band's comeback, "Interlude: Shadow", rapped by Suga and released on 10 January, addresses the shadows and the darkness that go hand-in-hand with the light and attention shone on celebrities. The next comeback trailer, "Outro: Ego", performed by J-Hope, ends with his declaration of self and ego as he appears within a colourful city "in which the artist's current image is projected". In 2019, Italian rapper Marracash released the album Persona, which features many Jungian themes. Jung appeared on the cover art of the 2008 single "Metanoia" by American psychedelic rock band MGMT. Composer John Zorn released his composition Liber Novus inspired by Jung's Red Book in 2010 on the Tzadik CD Dictée/Liber Novus. English rock musician Peter Gabriel's song The Rhythm of the Heat from his 1982 album, is directly based on Carl Jung's experiences during his time in Africa. The working title for the song was "Jung in Africa". Peruvian musician Daniela Lalita has cited Jung's archetype of the "Great Mother" as a major influence on her works Madre and Trececerotres.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.